Inceptionr LLC Purchases New Shares in Halozyme Therapeutics, Inc. $HALO

Inceptionr LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 11,923 shares of the biopharmaceutical company’s stock, valued at approximately $771,000.

Several other hedge funds and other institutional investors have also bought and sold shares of HALO. Arrowstreet Capital Limited Partnership grew its position in shares of Halozyme Therapeutics by 29.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after purchasing an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Halozyme Therapeutics by 1.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock worth $141,613,000 after purchasing an additional 25,731 shares during the period. Norges Bank acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $128,201,000. William Blair Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $124,031,000. Finally, Federated Hermes Inc. boosted its stake in shares of Halozyme Therapeutics by 8.5% in the fourth quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock valued at $105,972,000 after buying an additional 123,917 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $81.93 on Friday. The stock’s 50-day simple moving average is $73.08 and its 200 day simple moving average is $70.58. The firm has a market capitalization of $9.72 billion, a PE ratio of 29.47, a price-to-earnings-growth ratio of 0.34 and a beta of 0.84. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a twelve month low of $57.67 and a twelve month high of $82.99.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The firm had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Insider Activity

In other Halozyme Therapeutics news, CEO Helen Torley sold 1,923 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total transaction of $153,397.71. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $61,245,810.60. The trade was a 0.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director directly owned 14,462 shares of the company’s stock, valued at $1,084,650. This represents a 33.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 74,102 shares of company stock worth $5,205,798. Corporate insiders own 2.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Morgan Stanley cut their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $95.00 target price on shares of Halozyme Therapeutics in a report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $81.60.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.